Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with Crohn's disease in active phase
Phase 3
- Conditions
- Patients with Crohn's disease in active phase
- Registration Number
- JPRN-jRCT2080220189
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with Crohn's disease in active phase who are defined to show CDAI of 150 or higher but less than 250, and whose lesion is mainly observed at the end of ileum or lower part.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method